Citations

Clear

249 citation(s) found for "St-Denis, L".

Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans
Schu, Matthew , Farrell, John J. , Bennett, David A. , Buxbaum, Joseph D. , Byrd, Goldie S. , Ertekin‐Taner, Nilüfer , Evans, Denis A., Goate, Alison , Graff‐Radford, Neill R. , Kamboh, M. Ilyas , Kukull, Walter A. , Haines, Jonathan L. , Mayeux, Richard , Pericak‐Vance, Margaret A. , Schellenberg, Gerard D. , Baldwin, Clinton T., Fallin, M. Daniele , Farrer, Lindsay A. , Tsuang, Debby W. , Carroll, Steven L. , Logue, Mark W. , Vardarajan, Badri Narayan , Foroud, Tatiana , Manly, Jennifer J. , Lunetta, Kathryn L. , Bennett, David A. , Goate, Alison M

Mayo Clinic

Alzheimer's & Dementia | August 26, 2014 | Volume: 10 | Issue: 6 | Pages: 609

10.1016/j.jalz.2014.06.010 | PMID 25172201 Get It

AbstractBackgroundLess is known about the genetic basis of Alzheimer's disease (AD) in African Americans (AAs) than in non‐Hispanic whites.MethodsWhole exome sequencing (WES) was performed on seven AA AD cases. Disease association with potentially AD‐related variants from WES was assessed in an AA discovery cohort of 422 cases and 394 controls. Replication was sought in an AA sample of 1037 cases and 1869 controls from the Alzheimer Disease Genetics Consortium (ADGC).ResultsForty‐four single nucleotide polymorphisms (SNPs) from WES passed filtering criteria and were successfully genotyped. Nominally significant (P < .05) association to AD was observed with two African‐descent specific AKAP9 SNPs in tight linkage disequilibrium: rs144662445 (P = .014) and rs149979685 (P = .037). These associations were replicated in the ADGC sample (rs144662445: P = .0022, odds ratio [OR] = 2.75; rs149979685: P = .0022, OR = 3.61).ConclusionsBecause AKAP9 was not previously linked to AD risk, this study indicates a potential new disease mechanism.
Abstract B16: Inhibition of RNA Polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies
Drygin, Denis, O’Brien, Sean, Matthews, Geoff, Chesi, Marta , Bergsagel, Leif, Pearson, Rick, Hein, Nadine , Cullinane, Carleen M. , Zuber, Johannes , Lowe, Scott W. , Johnstone, Ricky W. , Pearson, Rick, McArthur, Grant A. , Hannan, Ross D.

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 19_Supplement | Pages: B16-B16

10.1158/1538-7445.fbcr13-b16 Get It

Abstract Malignant transformation is commonly associated with dysregulated ribosome biogenesis and for more than 100 years, pathologist have utilized the increase in size and number of nucleoli, the site of ribosome biogenesis as a marker for aggressive malignancies. Recently we demonstrated that hyperactivated RNA Polymerase I (Pol I) transcription, a rate limiting step in ribosome biogenesis, can be specifically targeted by the small molecule inhibitor, CX-5461. When evaluated for its anti-proliferative activity against a panel of genetically diverse human cancer cell lines, those derived from p53 wild type haemotological malignancies were the most sensitive (Drygin et al., Cancer Research, 2011). Evaluation of whether Pol I transcription inhibition could serve as therapeutic strategy in vivo revealed that CX-5461 administration significantly prolongs the overall survival of Eμ-Myc lymphoma bearing mice (Bywater et al., Cancer Cell, 2012). This survival advantage was associated with rapid activation of the ribosomal protein (Rp)-MDM2-p53 nucleolar stress response (Deisenroth et al., Oncogene, 2010) and subsequent induction of tumour-specific p53-dependent apoptosis (Bywater et al. Cancer Cell, 2012). New data and future directions: To further explore the therapeutic potential of Pol I transcription inhibition in haemotological cancers that are refractory to standard therapy, we employed mouse models of MLL-driven Acute Myeloid Leukemia (AML) (MLL/AF9 + Nras and MLL/ENL + Nras) (Zuber et al., Genes Dev, 2009) and V*κ-Myc-driven Multiple Myeloma (MM) (Chesi et al. Cancer Cell, 2009). CX-5461 administration significantly increased the overall survival time of AML-bearing mice (MLL/ENL Nras 17 days for vehicle vs 36 days for drug, P&lt;0.0001; MLL/AF9 Nras 15 days for vehicle vs 23 days for drug, P 0.0009))without severe adverse effects. The extended survival of MLL-driven AML bearing mice was associated with acute activation of p53, an aberrant G2/M cell cycle progression and consequently a delay in tumour progression as monitored by bioluminescence-imaging. In contrast to CX-5461, treatment of AML -bearing mice with Cytarabine/Doxorubicin, a regime used as standard-therapy in the clinic failed to induce p53 in MLL-driven AML resulting in a significantly less survival time than for CX-5461. In ongoing experiments with MM-bearing mice, chronic CX-5461 administration robustly reduced the secretion of serum monoclonal Ig, as detected by serum protein electrophoresis (SPEP), and significantly prolonged survival time demonstrating that CX-5461 possess potent anti-tumour activity in this highly refractory MM model. Analysis of the molecular mechanism responsible for the therapeutic benefit of CX-5461 in MM is ongoing but appears to involve both p53 mediated apoptosis and aberrant cell cycle progression. Conclusion: These data demonstrate that hyperactivated Pol I transcription can be successfully targeted through small molecule inhibitors to therapeutically treat models of human AML and MM that are refractory to standard therapy.. Based on these and published results (Bywater et al., Cancer Cell 2012) and a favorable toxicology profile, we have launched a first-in-human clinical trial of this first in class drug, CX-5461 in patients with hematological malignancies. The outcomes of this trial will offer valuable insights as to whether inhibition of ribosome synthesis might offer a new non-genotoxic therapy approach in the fight against cancers, which are highly refractory to standard-therapies. Citation Format: Nadine Hein, Denis Drygin, Sean O'Brien, Carleen Cullinane, Geoff Matthews, Marta Chesi, Leif Bergsagel, Johannes Zuber, Scott Lowe, Ricky Johnstone, Rick Pearson, Grant McArthur, Ross Hannan. Inhibition of RNA Polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies. [abstract]. In: Proceedings of the Third AACR International Conference on Frontiers in Basic Cancer Research; Sep 18-22, 2013; National Harbor, MD. Philadelphia (PA): AACR; Cancer Res 2013;73(19 Suppl):Abstract nr B16.
Sequence of Events in Measles Virus Replication: Role of Phosphoprotein-Nucleocapsid Interactions
Brunel, Joanna , Chopy, Damien, Dosnon, Marion, Bloyet, Louis-Marie , Devaux, Patricia , Urzua, Érica, Cattaneo, Roberto , Longhi, Sonia , Gerlier, Denis , Gerlier, Denis

Mayo Clinic

Journal of Virology | July 10, 2014 | Volume: 88 | Issue: 18 | Pages: 10851-10863

10.1128/jvi.00664-14 | PMID 25008930 Get It

ABSTRACT The genome of nonsegmented negative-strand RNA viruses is tightly embedded within a nucleocapsid made of a nucleoprotein (N) homopolymer. To ensure processive RNA synthesis, the viral polymerase L in complex with its cofactor phosphoprotein (P) binds the nucleocapsid that constitutes the functional template. Measles virus P and N interact through two binding sites. While binding of the P amino terminus with the core of N (N CORE ) prevents illegitimate encapsidation of cellular RNA, the interaction between their C-terminal domains, P XD and N TAIL is required for viral RNA synthesis. To investigate the binding dynamics between the two latter domains, the P XD F497 residue that makes multiple hydrophobic intramolecular interactions was mutated. Using a quantitative mammalian protein complementation assay and recombinant viruses, we found that an increase in P XD -to-N TAIL binding strength is associated with a slower transcript accumulation rate and that abolishing the interaction renders the polymerase nonfunctional. The use of a newly developed system allowing conditional expression of wild-type or mutated P genes, revealed that the loss of the P XD -N TAIL interaction results in reduced transcription by preformed transcriptases, suggesting reduced engagement on the genomic template. These intracellular data indicate that the viral polymerase entry into and progression along its genomic template relies on a protein-protein interaction that serves as a tightly controlled dynamic anchor. IMPORTANCE Mononegavirales have a unique machinery to replicate RNA. Processivity of their polymerase is only achieved when the genome template is entirely embedded into a helical homopolymer of nucleoproteins that constitutes the nucleocapsid. The polymerase binds to the nucleocapsid template through the phosphoprotein. How the polymerase complex enters and travels along the nucleocapsid template to ensure uninterrupted synthesis of up to ∼6,700-nucleotide messenger RNAs from six to ten consecutive genes is unknown. Using a quantitative protein complementation assay and a biGene-biSilencing system allowing conditional expression of two P genes copies, the role of the P-to-N interaction in polymerase function was further characterized. We report here a dynamic protein anchoring mechanism that differs from all other known polymerases that rely only onto a sustained and direct binding to their nucleic acid template.
BMP-2, Hypoxia, and COL1A1 / HtrA1 siRNAs Favor Neo-Cartilage Hyaline Matrix Formation in Chondrocytes
Ollitrault, David , Legendre, Florence , Drougard, Carole , Briand, Mélanie, Bénateau, Hervé, Goux, Didier , Chajra, Hanane , Vivien, Denis , Shridhar, Vijayalakshmi, Baldi, Alfonso , Mallein‐Gérin, Frédéric , Boumédiene, Karim , Demoor, Magali , Poulain, Laurent , Hartmann, Daniel Jean , Galéra, Philippe

Mayo Clinic

Tissue Engineering Part C: Methods | June 23, 2014 | Volume: 21 | Issue: 2 | Pages: 133-147

10.1089/ten.tec.2013.0724 | PMID 24957638 Get It

Evolution evolves: physiology returns to centre stage
Joyner, Michael J. , Müller, Gerd B. , Omholt, Stig W. , Noble, Denis , Jablonka, Eva , Joyner, Michael J

Mayo Clinic

The Journal of Physiology | June 1, 2014 | Volume: 592 | Issue: 11 | Pages: 2237-2244

10.1113/jphysiol.2014.273151 | PMID 24882808 Get It

Cardiopulmonary Exercise Testing
Marciniuk, Darcy D. , Johnson, Bruce D. , Neder, José Alberto , O’Donnell, Denis E.

Mayo Clinic

Pulmonary Medicine | June 9, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-1

10.1155/2013/686104 | PMID 23840951 Get It

Regulatory and Reimbursement Innovation
Lindor, Rachel A. , Allocco, Scott J., Cheatham, Lee, Cortese, Denis A., Hall, Ralph F., Mangold, William J., Pizziconi, Vincent , Poste, George, Quinn, Bruce, Roth, Mollie, Saks, Michael J. , Wassman, E. Robert , Woosley, Raymond L. , Marchant, Gary E. , Lindor, Rachel A

Mayo Clinic

Science Translational Medicine | March 13, 2013 | Volume: 5 | Issue: 176 | Pages: No page available

10.1126/scitranslmed.3005437 | PMID 23486776 Get It

Coverage with evidence development and parallel review for molecular diagnostics aid regulation and reimbursement.
Faculty Opinions recommendation of Impact of biopsy on the accuracy of endorectal ultrasound staging of rectal tumors.
Heppell, Jacques, Bouchard, Philippe

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1124872.620080 Get It

Faculty Opinions recommendation of Randomized, controlled, prospective trial of the use of a mesh to prevent parastomal hernia.
Heppell, Jacques, Bouchard, Philippe

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1161348.621853 Get It